Reference

Use of amtolmetin guacil as an antiinflammatory agent, which also inhibits gastric secretion

Use of amtolmetin guacil as an antiinflammatory agent, which also inhibits gastric secretion. Anzalone, Sergio (Medosan Ricerca S.R.L., Italy). Eur. Pat. Appl. EP 755679 A2 29 Jan 1997, 6 pp. DESIGNATED STATES: R: BE, CH, DE, DK, ES, FR, GB, GR, LI, NL, PT, SE. (English). (European Patent Organization). CODEN: EPXXDW. CLASS: ICM: A61K031-40. APPLICATION: EP 1996-830388 10 Jul 1996. PRIORITY: IT 1995-RM484 14 Jul 1995. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) The use of an amtolmetin guacil without gastrolesive activity and which, unlike other known nonsteroidal anti-inflammatory drugs (NSAIDs) inhibits the gastric secretion stimulated with the three physiol. 87344-06-7 is just another one chemical used in this study. agents histamine, acetylcholine and gastrin and shows, consequently, protective action on the gastric mucosa, is disclosed. .

Anti-PSGL-1 antibodies, and diagnostic and therapeutic use

Correction of: Anti-PSGL-1 antibodies, and diagnostic and therapeutic use. Levanon, Avigdor; Vogel, Tikva; Plaksin, Daniel; Peretz, Tuvia; Amit, Boaz; Cooperman, Lena; Hagay, Yocheved; Szanton, Esther; Kanfi, Yariv; Ben-Levy, Rachel (Savient Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2005005455 A2 20 Jan 2005, 108 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07K. APPLICATION: WO 2004-US21099 30 Jun 2004. PRIORITY: US 2003-2003/610840 30 Jun 2003. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 9, 15, 26 The invention provides antibodies that bind an epitope of PSGL-1 comprising the motif DXYD, wherein X represents any amino acid or the covalent linkage between D and Y, and Y is sulfated, which antibody can be complexed with one or more copies of a therapeutic or diagnostic agent. 87344-06-7 are also occured in this study. The antibodies can be used in a method of inducing antibody-dependent cell cytotoxicity and/or stimulating natural killer (NK) cells or T cells. In addn., by administering these antibodies to a patient in need thereof, a method of inducing cell death is provided. A method of preventing infection by a virus (e.g., HIV) by administering to a patient in need thereof an antibody of the invention is also provided. The invention also provides a method of introducing an agent into a cell that expresses sulfated PSGL-1 by coupling or complexing an agent to an antibody of the present invention and administering the complex to the cell. Finally, the present invention provides methods of diagnosis, prognosis and staging using the antibodies. Prepn. of e.g. a morpholinodaunorubicin-antibody conjugate is included. .